161 related articles for article (PubMed ID: 11284945)
1. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
Venditti M; Monaco M; Micozzi A; Tarasi A; Friedrich A; Martino P
Clin Microbiol Infect; 2001 Jan; 7(1):37-9. PubMed ID: 11284945
[No Abstract] [Full Text] [Related]
2. Susceptibility to antimicrobial agents of Stenotrophomonas maltophilia isolated from patients with cancer and bacteremia.
Krcmery V; Trupl J; Svetlansky I
Clin Infect Dis; 2001 Jun; 32(11):1656. PubMed ID: 11340542
[No Abstract] [Full Text] [Related]
3. Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia.
Korakianitis I; Mirtsou V; Gougoudi E; Raftogiannis M; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2010 Oct; 36(4):387-9. PubMed ID: 20674284
[No Abstract] [Full Text] [Related]
4. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
5. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Passerini de Rossi B; García C; Calenda M; Vay C; Franco M
Int J Antimicrob Agents; 2009 Sep; 34(3):260-4. PubMed ID: 19362452
[TBL] [Abstract][Full Text] [Related]
6. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.
Micozzi A; Venditti M; Monaco M; Friedrich A; Taglietti F; Santilli S; Martino P
Clin Infect Dis; 2000 Sep; 31(3):705-11. PubMed ID: 11017819
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
8. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.
Giamarellos-Bourboulis EJ; Karnesis L; Galani I; Giamarellou H
Antimicrob Agents Chemother; 2002 Dec; 46(12):3997-9. PubMed ID: 12435710
[TBL] [Abstract][Full Text] [Related]
9. [Molecular epidemiology of Stenotrophomonas maltophilia strains isolated from paediatric patients].
Köseoğlu O; Sener B; Gür D
Mikrobiyol Bul; 2004; 38(1-2):9-19. PubMed ID: 15293897
[TBL] [Abstract][Full Text] [Related]
10. Stenotrophomonas maltophilia bacteremia in pediatric patients-- a 10-year analysis.
Wu PS; Lu CY; Chang LY; Hsueh PR; Lee PI; Chen JM; Lee CY; Chan PC; Chang PY; Yang TT; Huang LM
J Microbiol Immunol Infect; 2006 Apr; 39(2):144-9. PubMed ID: 16604247
[TBL] [Abstract][Full Text] [Related]
11. [Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area].
Tao CM; Li XC; Lü XJ; Li P; Yu RJ; Gao YY; Chen HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):91-3. PubMed ID: 14981826
[TBL] [Abstract][Full Text] [Related]
12. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital.
Sattler CA; Mason EO; Kaplan SL
Clin Infect Dis; 2000 Dec; 31(6):1321-30. PubMed ID: 11095997
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
Hamamoto K; Shimizu T; Fujimoto N; Zhang Y; Arai S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1908-10. PubMed ID: 11353651
[TBL] [Abstract][Full Text] [Related]
14. Emergence of fluoroquinolone-resistant Stenotrophomonas maltophilia in blood isolates causing bacteremia: molecular epidemiology and microbiologic characteristics.
Cha MK; Kang CI; Kim SH; Cho SY; Ha YE; Chung DR; Peck KR; Song JH
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):210-2. PubMed ID: 27117514
[TBL] [Abstract][Full Text] [Related]
15. Pseudooutbreak of Stenotrophomonas maltophilia bacteremia in a general ward.
Park YS; Kim SY; Park SY; Kang JH; Lee HS; Seo YH; Cho YK
Am J Infect Control; 2008 Feb; 36(1):29-32. PubMed ID: 18241733
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia.
Chen CY; Tsay W; Tang JL; Tien HF; Chen YC; Chang SC; Hsueh PR
Epidemiol Infect; 2010 Jul; 138(7):1044-51. PubMed ID: 19941686
[TBL] [Abstract][Full Text] [Related]
17. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia.
Valdezate S; Vindel A; Baquero F; Cantón R
Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):908-11. PubMed ID: 10691206
[TBL] [Abstract][Full Text] [Related]
19. [Nosocomial Stenotrophomonas maltophilia infections in a university hospital].
Caylan R; Yilmaz G; Sucu N; Bayraktar O; Aydin K; Kaklikkaya N; Aydin F; Köksal I
Mikrobiyol Bul; 2005 Jan; 39(1):25-33. PubMed ID: 15900834
[TBL] [Abstract][Full Text] [Related]
20. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen.
Senol E
J Hosp Infect; 2004 May; 57(1):1-7. PubMed ID: 15142709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
